

October 28, 2016

Eisai Co., Ltd.
EA Pharma Co., Ltd.

**Application Submitted for Proton Pump Inhibitor Pariet® in Japan
Seeking Approval for Additional Dosage and Administration for
Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis**

Eisai Co., Ltd. (Headquarters, Tokyo; CEO, Haruo Naito; "Eisai") and Eisai's subsidiary for gastrointestinal disease area EA Pharma Co., Ltd. (Headquarters, Tokyo; President & CEO, Hajime Shimizu; "EAn

More Information

1 About Pariet

Pariet is a proton pump inhibitor that was discovered and developed by Eisai Co., Ltd. First launched in Japan in 1997, it is approved in more than 100 countries and territories worldwide. In Japan, Pariet is indicated for multiple uses, including for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, non-erosive gastroesophageal reflux disease, the prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy and as an adjunctive therapy in *Helicobacter pylori* (*H. pylori*) eradication, and is available in 5 mg, 10 mg and 20 mg tablet formulations based on evidence collected in Japanese patients. In addition, in